ArticleJournal of food science2026
Modulatory Effect of the Alfalfa Polysaccharide Fraction II on Cyclophosphamide-Induced Immunosuppression in Mice.
Article in Journal of food science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study investigated the protective effects of alfalfa polysaccharide fraction II (APS-II) on immunosuppression induced by cyclophosphamide (CTX) in mice. APS-II was extracted using ultrasound-assisted enzymatic extraction method and purified by DEAE-52 cellulose chromatography. Its structural characteristics, including molecular weight (Mw), monosaccharide composition, and thermal stability, were analyzed. A CTX-induced immunosuppressed mouse model was established to evaluate the effects of APS-II on immune organ indices, serum cytokines, antioxidant indicators in liver and spleen tissues, and intestinal microbiota. Results showed that APS-II, with main Mw of 28.05 kDa, consisted of glucose, galactose, mannose, arabinose, glucuronic acid, and rhamnose in the molar ratio of 8.04:1.22:1.18:0.92:1:0.06. Treatment with medium and high doses of APS-II significantly restored thymus and spleen indices (p < 0.05), increased serum cytokine levels of interleukin-2 (IL-2), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) (p < 0.05), and ameliorated spleen and thymus histopathology. Antioxidant parameters of total antioxidant capacity (T-AOC), catalase (CAT), and glutathione (GSH) were elevated, and malondialdehyde (MDA) was reduced, reaching significance at the high dose (p < 0.05). Additionally, APS-II reshaped the gut microbiota by increasing Bacteroidota abundance and reducing the Firmicutes/Bacteroidota ratio (p < 0.05), enriching Muribaculaceae and Lactobacillus (p < 0.01), while decreasing potentially pathogenic Rikenellaceae. In conclusion, APS-II provides significant protection against CTX-induced immunosuppression and holds promise as a functional food ingredient for immune health. PRACTICAL APPLICATIONS: Alfalfa polysaccharide fraction II (APS-II) exerts a protective effect on mice with CTX-induced immunosuppression, laying the scientific foundation for its development as an immunomodulatory ingredient in functional foods and dietary supplements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.